Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $53.84 million. The enterprise value is -$31.17 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 20.63 million shares outstanding. The number of shares has increased by 22.64% in one year.
| Current Share Class | 20.63M |
| Shares Outstanding | 20.63M |
| Shares Change (YoY) | +22.64% |
| Shares Change (QoQ) | +85.91% |
| Owned by Insiders (%) | 7.61% |
| Owned by Institutions (%) | 30.41% |
| Float | 15.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.33, with a Debt / Equity ratio of 0.05.
| Current Ratio | 16.33 |
| Quick Ratio | 15.86 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.90% and return on invested capital (ROIC) is -29.39%.
| Return on Equity (ROE) | -45.90% |
| Return on Assets (ROA) | -28.11% |
| Return on Capital (ROIC) | -29.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.51M |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.07% in the last 52 weeks. The beta is 1.79, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.79 |
| 52-Week Price Change | +94.07% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 74.95 |
| Average Volume (20 Days) | 202,964 |
Short Selling Information
The latest short interest is 2.32 million, so 11.24% of the outstanding shares have been sold short.
| Short Interest | 2.32M |
| Short Previous Month | 2.15M |
| Short % of Shares Out | 11.24% |
| Short % of Float | 15.29% |
| Short Ratio (days to cover) | 19.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -44.25M |
| Pretax Income | -40.69M |
| Net Income | -40.69M |
| EBITDA | -43.90M |
| EBIT | -44.25M |
| Earnings Per Share (EPS) | -$2.94 |
Full Income StatementBalance Sheet
The company has $89.58 million in cash and $4.98 million in debt, giving a net cash position of $84.60 million or $4.10 per share.
| Cash & Cash Equivalents | 89.58M |
| Total Debt | 4.98M |
| Net Cash | 84.60M |
| Net Cash Per Share | $4.10 |
| Equity (Book Value) | 92.05M |
| Book Value Per Share | 4.46 |
| Working Capital | 86.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.33 million and capital expenditures -$92,000, giving a free cash flow of -$33.42 million.
| Operating Cash Flow | -33.33M |
| Capital Expenditures | -92,000 |
| Free Cash Flow | -33.42M |
| FCF Per Share | -$1.62 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |